NCT00114361View on ClinicalTrials.gov

48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

April 30, 2010

Conditions
Hepatitis B
Interventions
DRUG

Ribavirin

1200 mg a day, 48 weeks

DRUG

Peginterferon alpha 2a

180 µg per week, 48 weeks

Trial Locations (1)

3000CA

Erasmus MC department hepatology, Rotterdam

Sponsors
All Listed Sponsors
lead

Foundation for Liver Research

OTHER

NCT00114361 - 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection | Biotech Hunter | Biotech Hunter